Treventis was represented at the BIO Digital International Convention (for a second year in a row, held virtually due to COVID-19) with more than 6,000 attendees and 55 countries represented. This conference hosts delegates passionate about creating new opportunities to partner and collaborate on innovative drug projects aimed at improving the lives of patients.
This year, Treventis CEO Christopher Barden networked with dozens of other companies and partners about the company’s technology and programs in protein misfolding disease therapeutics, including the tremendous progress being made towards candidate selection in our dual-action Alzheimer’s / tauopathy program.